149 related articles for article (PubMed ID: 24527759)
1. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
Sale MJ; Cook SJ
Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
[TBL] [Abstract][Full Text] [Related]
2. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
3. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik.
Lopez J; Hesling C; Prudent J; Popgeorgiev N; Gadet R; Mikaelian I; Rimokh R; Gillet G; Gonzalo P
Cell Death Differ; 2012 Sep; 19(9):1459-69. PubMed ID: 22388352
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
5. CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.
Gilley R; Lochhead PA; Balmanno K; Oxley D; Clark J; Cook SJ
Cell Signal; 2012 Jan; 24(1):170-80. PubMed ID: 21924351
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
7. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
Sale MJ; Cook SJ
Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
9. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
Tsubaki M; Itoh T; Satou T; Imano M; Komai M; Ogawa N; Mukai J; Nishida S
Biochem Pharmacol; 2013 Jan; 85(2):163-72. PubMed ID: 23085435
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
[TBL] [Abstract][Full Text] [Related]
12. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
13. c-Cbl is not required for ERK1/2-dependent degradation of BimEL.
Wiggins CM; Band H; Cook SJ
Cell Signal; 2007 Dec; 19(12):2605-11. PubMed ID: 17884340
[TBL] [Abstract][Full Text] [Related]
14. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
15. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
16. BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation.
Wiggins CM; Tsvetkov P; Johnson M; Joyce CL; Lamb CA; Bryant NJ; Komander D; Shaul Y; Cook SJ
J Cell Sci; 2011 Mar; 124(Pt 6):969-77. PubMed ID: 21378313
[TBL] [Abstract][Full Text] [Related]
17. Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.
Brosseau C; Dousset C; Touzeau C; Maïga S; Moreau P; Amiot M; Le Gouill S; Pellat-Deceunynck C
Cell Death Dis; 2014 Aug; 5(8):e1389. PubMed ID: 25165875
[TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
[TBL] [Abstract][Full Text] [Related]
19. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells.
Chen K; Tu Y; Zhang Y; Blair HC; Zhang L; Wu C
J Biol Chem; 2008 Feb; 283(5):2508-17. PubMed ID: 18063582
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ
Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
